{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:14:30Z","timestamp":1791566070634,"version":"4.3.4"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.clgc.2015.01.010","type":"journal-article","created":{"date-parts":[[2015,1,30]],"date-time":"2015-01-30T12:37:35Z","timestamp":1422621455000},"page":"e205-e208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel"],"prefix":"10.1016","volume":"13","author":[{"given":"Aurelius","family":"Omlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rothermundt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Cathomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann S.","family":"De Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liji","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2015.01.010_bib1","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2015.01.010_bib2","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2015.01.010_bib3","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after\u00a0docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2015.01.010_bib4","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.eururo.2012.08.058","article-title":"Cabazitaxel plus prednisone for\u00a0metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme","volume":"63","author":"Heidenreich","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2015.01.010_bib5","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clgc.2013.04.004","article-title":"Cabazitaxel in patients with metastatic castration-resistant prostate cancer: results of a compassionate use program in the Netherlands","volume":"11","author":"Wissing","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2015.01.010_bib6","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1517\/14740338.2014.939583","article-title":"Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program","volume":"13","author":"Castellano","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clgc.2015.01.010_bib7","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2217\/fon.13.256","article-title":"Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer","volume":"10","author":"Bracarda","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.clgc.2015.01.010_bib8","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1093\/annonc\/mdt194","article-title":"Impact of cabazitaxel on 2-year survival and\u00a0palliation of tumour-related pain in men with metastatic castration-resistant\u00a0prostate cancer treated in the TROPIC trial","volume":"24","author":"Bahl","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2015.01.010_bib9","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1470-2045(13)70184-0","article-title":"Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial","volume":"14","author":"Tannock","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2015.01.010_bib10","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/annonc\/mdl056","article-title":"Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG)","volume":"17","author":"Trudeau","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2015.01.010_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejca.2012.07.008","article-title":"Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study","volume":"49","author":"Dieras","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2015.01.010_bib12","first-page":"32","article-title":"Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial (abstract LBA2)","author":"Sweeney","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2015.01.010_bib13","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/nrneurol.2014.211","article-title":"Mechanism-based treatment for\u00a0chemotherapy-induced peripheral neuropathic pain","volume":"10","author":"Sisignano","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.clgc.2015.01.010_bib14","first-page":"1","article-title":"Metabolism of the taxanes including nab-paclitaxel","author":"Joerger","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clgc.2015.01.010_bib15","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1158\/1535-7163.MCT-14-0265","article-title":"Antiproliferative mechanism of action of the novel taxane cabazitaxel as compared with the parent compound docetaxel in MCF7 breast cancer cells","volume":"13","author":"Azarenko","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clgc.2015.01.010_bib16","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2147\/DDDT.S64940","article-title":"Preclinical profile of cabazitaxel","volume":"8","author":"Vrignaud","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clgc.2015.01.010_bib17","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","article-title":"Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel","volume":"12","author":"Desai","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2015.01.010_bib18","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","article-title":"Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial","volume":"30","author":"Socinski","year":"2012","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767315000129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767315000129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:25:52Z","timestamp":1761564352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767315000129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S1558767315000129"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2015.01.010","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2015.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}